8-KEarnings & ResultsExhibits & Filings

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Financial Results (Feb 13, 2014)

Filed February 13, 2014For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. (ALNY) filed an 8-K on February 13, 2014, primarily to announce its financial results for the fourth quarter and full year ended December 31, 2013. This filing serves as a notification to investors regarding the company's financial performance and condition as of that period. The press release containing these results, furnished as Exhibit 99.1, is the key document for investors seeking details on revenue, expenses, and any significant financial developments. While the 8-K itself is a procedural filing, the underlying press release is critical for understanding Alnylam's operational and financial status. Investors should review the press release to assess the company's financial health, cash position, and any forward-looking statements or strategic updates that may have been provided alongside the reported figures. This information is essential for evaluating Alnylam's progress and outlook in the competitive biotechnology landscape.

Key Highlights

  • 1Company announced financial results for the quarter and year ended December 31, 2013.
  • 2The announcement was made on February 13, 2014.
  • 3The full press release containing the financial results is furnished as Exhibit 99.1 to this 8-K.
  • 4The filing is a Current Report on Form 8-K, indicating material events or information.
  • 5Information furnished under Item 2.02 is not considered 'filed' for certain SEC liability purposes but is still important for investor awareness.
  • 6The report details Alnylam's financial condition and results of operations for the specified period.

Frequently Asked Questions

The primary purpose of this 8-K filing is to announce Alnylam Pharmaceuticals, Inc.'s financial results for the fourth quarter and the full fiscal year ended December 31, 2013. It formally reports these results to the SEC and provides access to the detailed press release containing this information.

The detailed financial results are provided in the press release dated February 13, 2014, which is furnished as Exhibit 99.1 to this Form 8-K filing. Investors should refer to this exhibit for comprehensive financial data.

No, the information furnished under Item 2.02 of this Form 8-K, including the press release, is generally not deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, nor is it automatically incorporated by reference into other SEC filings, unless specifically stated.

This section indicates that the company is providing an update on its financial performance (revenues, profitability, etc.) and its overall financial health (assets, liabilities, cash flow) as of and for the period ending December 31, 2013. Investors use this information to gauge the company's current business performance and financial stability.